Indaptus Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2024 · 2023 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(10,890,980) | $(11,420,691) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 735 | 964 | ||
| Stock-based compensation | 2,001,727 | 2,220,413 | ||
| Interest earned on marketable securities | - | (430,993) | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current and non- current assets | 634,419 | (84,568) | ||
| Accounts payable and other current liabilities | (673,829) | (1,088,785) | ||
| Operating lease right-of-use asset and liability, net | 487 | 290 | ||
| Net cash used in operating activities | (8,927,441) | (10,803,370) | ||
| Cash flows from investing activities: | ||||
| Maturity of marketable securities | - | 24,000,000 | ||
| Purchase of marketable securities | - | (6,859,432) | ||
| Net cash provided by investing activities | - | 17,140,568 | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of shares of common stock and warrants | 3,375,590 | - | ||
| Issuance costs | (429,516) | - | ||
| Net cash provided by financing activities | 2,946,074 | - | ||
| Net (decrease) increase in cash and cash equivalents | (5,981,367) | 6,337,198 | ||
| Cash and cash equivalents at beginning of period | 13,362,053 | 9,626,800 | ||
| Cash and cash equivalents at end of period | $7,380,686 | $15,963,998 | ||
| Noncash investing and financing activities | ||||
| Transaction costs in accounts payable and other current liabilities | $129,993 | $ | - | |
| Change in unrealized gain/loss on marketable securities | $ | - | $(96,434) | |
| ASC 842 lease renewal option exercise | $ | - | $236,506 | |
| Reclassification of security deposit | $ | - | $16,477 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.